Key Takeaways
- Flat revenue, margin reset: Revenue held at ~Rs 7,000 Cr despite the Revlimid wind-down, but EBITDA margin fell to ~17.7% as the high-margin generic exited and R&D spend stepped up to ~7% of sales.
- Lanreotide disruption is the new overhang: A US FDA inspection at partner Pharmathen paused production, limiting supply in Q3 and pushing any meaningful resupply to H1 FY27. The US revenue guidance is being revised down as a result.
- The pipeline is loaded, but the payoff is back-ended: Four respiratory launches including generic Advair are due in the next 12 months, plus three peptide assets in FY27. Management says two respiratory products could be among Cipla's largest ever, but they replace Revlimid at lower profitability.
- One-India and EMEU are the steady engines: India grew 10% YoY with chronic mix strengthening to 62.3%, while EMEU posted its fourth straight quarter above $100 mn. Both provide ballast while the US resets.
- What to watch next quarter: FY27 margin and revenue guidance (promised after the annual operating plan is finalized), any FDA movement on the Pharmathen site, and the pace of the first big respiratory launches.
The Revlimid Cliff and Margin Reset
- The generic Revlimid cycle is effectively over: Most shipments landed in the September quarter, with only a small portion in December. The sequential US revenue decline was driven largely by this tail-off, with a smaller contribution from Lanreotide supply disruption.
- Margins fell below internal expectations: EBITDA margin landed at ~17.7%, driven by the Revlimid exit, lower-than-anticipated Lanreotide performance, and stepped-up investment in R&D, manufacturing readiness, and facility derisking.
- The structural margin shift from pre-Revlimid days: Margins have moved from ~21% (pre-Lenalidomide) to the current level because R&D has risen from ~5-5.5% to ~7% of sales (a 1.5-2% dilution), plus organic growth investments and facility derisking spend over the last 1-2 years.
- R&D spend is lumpy and elevated: The 7% R&D-to-sales ratio sits across material costs, other costs, and people costs. This quarter included a one-time purchase of R&D APIs and oligonucleotides that may not recur in Q4. R&D also includes litigation costs for the US and other markets.
- A cost optimization program is running: Some benefit may come towards the end of this year, with more full-year benefits next year.
- New launches will fill the revenue hole, but at lower profitability: Collectively, upcoming launches will make up for the generic-side revenue drop from Revlimid, but at lower profitability. Respiratory assets are all in-house, so they will carry very good gross margins.
Ashish Adukia: "It will be lower profitability than Revlimid and it also depends on, by the way, on timing. So, when you launch a system collectively, I am saying that it will make up, it will be lower profitability, but important to note is that our respiratory assets are all in-house. So, they will come at a very good gross margin."
Lanreotide: The Supply Shock
- Partner facility hit with FDA observations: Pharmathen, Cipla's manufacturing partner for Lanreotide, had a US FDA inspection resulting in nine 483 observations. Production was temporarily paused, leaving only limited supply available in the December quarter.
- The impact versus plan is much larger than the Q3 sales dip: Management characterized the disruption as significantly bigger than what showed up in the quarter's revenue, implying a material hole in the FY27 outlook.
- Resupply timeline pushed to H1 FY27: Lanreotide is expected to resume only in the first half of FY27, and until manufacturing restarts, the product remains in limited supply subject to quality clearance of existing stocks.
- Derisking via a second site is in motion: Discussions with the partner are advanced for transferring the product to a second site, though not in the same market. Earlier resumption will come from the existing site subject to USFDA clearance.
- US revenue guidance is being revised down: Management confirmed the $1 billion US revenue target by FY27 will have to be revised downward because Lanreotide will not be in Q4.
- No inventory write-down taken: Whatever Lanreotide was sold in Q3 carried a normal material cost; no adjustment was made to inventory.
Ashish Adukia: "No, there has been no adjustment in the inventory that we have had on account of Lanreotide. Whatever we have sold in this quarter of Lanreotide, a normal material cost against that is what is booked."
The Pipeline: Respiratory and Peptides
- Four significant respiratory launches are coming, three filed from US facilities: The launch calendar includes two big respiratory launches and one smaller one (generic Advair) in the next six months, with another big respiratory launch likely towards the end of the year.
- Two products could be among Cipla's largest ever: Management indicated that one, if not both, of the big respiratory products could rank in the top 2 or top 3 by revenue for the company, excluding Lenalidomide but including Lanreotide.
- Three more peptide assets are expected in FY27: None of these will come from the Pharmathen facility. A smaller peptide launch is due in 0-6 months, with a larger, potentially exclusive peptide launch in 6-12 months.
- Generic Victoza approval is in hand: Launch is expected during the quarter.
- Management is confident on execution: There are no reasons to suspect issues with the upcoming respiratory and peptide launches.
- Competitive details are withheld: Management declined to confirm whether the respiratory assets include Symbicort or to disclose the total addressable market and competitive landscape, citing competitive reasons.
Umang Vohra: "What I was trying to say is that it's quite likely that one, if not both, could be one of the largest products for the Company."
India and EMEU: The Steady Engines
- One-India delivered 10% YoY growth: Key therapies outperformed the market, and the chronic mix strengthened to 62.3%. Priorities are to sustain growth momentum and outperform in both branded generics and trade generics.
- EMEU posted its fourth straight quarter above $100 mn: 7% YoY growth in USD terms, with margin stability maintained while leveraging internal pipeline assets. The priority is to deepen penetration in core markets.
- Strategic India moves add heft: Cipla signed an exclusive marketing and distribution agreement with Pfizer for four well-established brands, acquired Inzpera Health Sciences for pediatric pharmaceuticals, and launched Afrezza (inhaled insulin) and Yurpeak (once-weekly tirzepatide via Eli Lilly partnership).
- Galvus license made perpetual: Rs 1,100 Cr was paid to Novartis for perpetual rights to manufacture Galvus and combination products, a follow-up to the April 2023 in-licensing deal. This sits in intangibles, not on the P&L.
- Schedule M implementation is not a threat: Cipla is already at or better than the standards required, so no material impact is expected on the trade generics or branded generics business.
Achin Gupta: "From CIPLA perspective, we do not have much or any impact because we are already at or better than the standards that are asked for."
Regional and Base Business Dynamics
- North America base business ex-Revlimid grew double digits YoY: This includes Lanreotide and was achieved despite supply challenges in some key products and increased competition in new launches.
- Abraxane launch is off to a modest start: The launch coincided with other entrants, making it a competitive market. Cipla holds a single-digit market share and hopes to increase it.
- South Africa private market is strong, but primary revenues are weak: Secondary growth of 6.3% outperformed the market, but in-country channel destocking weighed on primary revenues. Normalization is expected by next quarter.
- The Indore facility re-inspection is expected anytime soon: This is a key regulatory milestone to watch.
- Semaglutide entry is on hold: Management will wait and watch how the market evolves. If an opportunity emerges at a lower price point to cover some market, Cipla can take that call, but not immediately. The focus is on tirzepatide.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 EBITDA margin | Land at around 21% | FY26 full year |
| Lanreotide resupply | Resume from existing site subject to USFDA clearance | H1 FY27 |
| Respiratory launches | Two big plus one smaller (Advair) launch | Next 6 months |
| Respiratory launch | Another big respiratory launch (likely Symbicort) | 6-12 months |
| Peptide launches | Three peptide assets, none from Pharmathen facility | FY27 |
| Generic Victoza launch | Approval received, launch expected | During the quarter |
| South Africa primary revenue | Normalization expected | Next quarter |
| US $1 bn revenue guidance | Will be revised downward (Lanreotide absent from Q4) | FY27 target |
| R&D spend | Try to keep around 6% of sales, with quarterly lumpiness | Ongoing |
| FY27 margin and revenue guidance | To be provided after annual operating plan is finalized | Next quarter |
| Cost optimization program | Some benefit towards end of this year, full-year benefits next year | FY27 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹7,074 cr, flat YoY |
| EBITDA margin (excl. other income) | 17.7%, decline driven by lower generic Revlimid revenues |
| Gross margin after material cost | 62.8%, decline driven by lenalidomide drop and product mix |
| Profit after tax | ₹676 cr, 9.6% of sales; includes one-time labour code impact of ₹276 cr in exceptional items |
| Total expenses | ₹3,187 cr, +13% YoY on planned R&D, manufacturing, and talent investments |
| R&D investments | ₹494 cr, 7.0% of revenue, +37.4% YoY |
| Effective tax rate | 24.5% |
| Net cash balance | ₹10,229 cr as of Dec 31, 2025, after dividend and Galvus payment; debt incl. lease liabilities ₹489 cr |
| FY26 EBITDA margin guidance | ~21%, lowered from prior expectation; Q3 EBITDA was 1.5%–2% below internal plan |
| One-India business growth | 10% YoY |
| Branded prescription growth | 10% YoY |
| Chronic mix | 62.3% YoY |
| Respiratory therapy growth | 11% YoY, outperformed IPM therapy growth by 400 bps (IQVIA quarter ended Dec '25) |
| Anti-diabetes and cardiac growth | 13% each YoY |
| Urology growth | 15% YoY |
| North America quarterly revenue | $167 million, includes small Lenalidomide contribution; base business ex-Lena grew double-digit YoY |
| U.S. Albuterol MDI market share | 22%, number one position (IQVIA week ending Dec 26, 2025) |
| South Africa private market secondary growth | 6.3%, outperformed market growth of 5.7% (IQVIA MAT Nov '25) |
| EMEU quarterly revenue | Above $100 million for fourth successive quarter, +7% YoY in USD terms |
| Brands in INR 100+ crore club | 30 brands, 4 added this quarter |
| Brands in IPM top 300 | 22 brands |
| Trade generics new launches | 8 new launches in the quarter |
| Lanreotide supply status | Production temporarily paused after partner Pharmathen received 9 USFDA 483 observations; resupply expected H1 FY27 |
| Galvus perpetual rights payment | ₹1,100 cr paid to Novartis, sitting in intangibles/capital advances |